Abstract: The present disclosure relates to a liquid-cooling radiating pipe and a vacuum interrupter with a built-in liquid-cooling radiating pipe, belonging to the field of vacuum circuit breakers. Based on an original structure of an vacuum interrupter, a liquid-cooling radiating pipe of a Tesla valve structure is arranged in a conductive rod of the vacuum interrupter with the built-in liquid-cooling radiating pipe, and liquid metal is used as a circulating coolant in the liquid-cooling radiating pipe, and by using the self-circulating flow of the liquid metal in the pipeline, the capacity of the conductive rod to dissipate heat to the outside is significantly increased, and the problem of excessive internal temperature rise of a vacuum circuit breaker is effectively solved.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.

Abstract: Disclosed is N-formyl vortioxetine, and also disclosed is a method for preparing the N-formyl vortioxetine and a stable solid preparation of vortioxetine.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.

Abstract: Disclosed is N-formyl vortioxetine, and also disclosed is a method for preparing the N-formyl vortioxetine and a stable solid preparation of vortioxetine.

Abstract: Disclosed is a preparation method for an azacitidine for injection, wherein each injection vial of azacitidine for injection contains 100 mg of azacitidine and 100 mg of mannitol. The preparation method comprises the steps of measuring 80% of the total volume of water for injection at a temperature of 2-6° C.; adding mannitol, and stirring to completely dissolved at a temperature of 2-6° C.; adding azacitidine, stirring to completely dissolved at a temperature of 2-6° C. to obtain an azacitidine solution for injection; filling each injection vial with 23 ml azacitidine solution for injection after filtration; freeze-drying at a preset temperature; and stoppering, capping and packaging after nitrogen filling. The preparation method has the advantages of a simple process, low energy consumption, high production efficiency and stable product quality.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.

Abstract: Disclosed is a preparation method for an azacitidine for injection, wherein each injection vial of azacitidine for injection contains 100 mg of azacitidine and 100 mg of mannitol. The preparation method comprises the steps of measuring 80% of the total volume of water for injection at a temperature of 2-6° C.; adding mannitol, and stirring to completely dissolved at a temperature of 2-6° C.; adding azacitidine, stirring to completely dissolved at a temperature of 2-6° C. to obtain an azacitidine solution for injection; filling each injection vial with 23 ml azacitidine solution for injection after filtration; freeze-drying at a preset temperature; and stoppering, capping and packaging after nitrogen filling. The preparation method has the advantages of a simple process, low energy consumption, high production efficiency and stable product quality.

Abstract: Disclosed are pharmaceutically acceptable PDE V inhibitor Formulations that are especially useful for treating male erectile and female sexual dysfunction and other physiological disorders.

Abstract: Disclosed are pharmaceutically acceptable PDE V inhibitor Formulations that are especially useful for treating male erectile and female sexual dysfunction and other physiological disorders.